Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0824 Yumanity
BioCentury & Getty Images


Reverse merger offers Yumanity faster, less risky path to NASDAQ

Aug 25, 2020 | 12:31 AM GMT

Despite continued demand for biotech IPOs, Yumanity has opted to take a less traditional route to the public markets in a move that it views as more efficient and less risky. 

On Monday, the company announced a reverse merger with Proteostasis Therapeutics

Read the full 628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers